

PE/Dazzle® 594 anti-human CD2

Catalog # / Size: 2101135 / 25 tests
2101140 / 100 tests

Clone: RPA-2.10

Isotype: Mouse IgG1, κ


Reactivity: Human, Non-human primate, Other

Preparation: The antibody was purified by affinity chromatography and conjugated with PE/Dazzle™ 594 under optimal conditions. The solution is free of unconjugated PE/Dazzle™ 594 and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Workshop Number: IV T085

Concentration: Lot-specific



Human peripheral blood lymphocytes stained with CD2 (clone RPA-2.10) PE/Dazzle™ 594 (filled histogram) or mouse IgG1, κ PE/Dazzle™ 594 isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

* PE/Dazzle™ 594 has a maximum excitation of 566 nm and a maximum emission of 610 nm.

Application Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections⁶ and blocking of T cell activation².

- Application References:**
1. Bell G, *et al.* 1995. *J. Immunol.* 155:2805.
 2. Bierer B, *et al.* 1989. *Annu. Rev. Immunol.* 7:579.
 3. Moingeon P, *et al.* 1989. *Immunol. Rev.* 111:111.

Description: CD2 is a 50 kD type I transmembrane glycoprotein also known as LFA-2, T11, and sheep red blood cell receptor (SRBC-R). This immunoglobulin superfamily member is expressed on thymocytes, T lymphocytes, NK cells, and thymic B cell subsets. The major ligand for CD2 is CD58 (also known as LFA-3). CD2 has also been reported to bind CD48, CD59, and CD15. CD2 plays a critical role in alternative T cell activation, T cell signaling, and cell-cell adhesion.

- Antigen References:**
1. Bell G, *et al.* 1995. *J. Immunol.* 155:2805.
 2. Bierer B, *et al.* 1989. *Annu. Rev. Immunol.* 7:579.
 3. Moingeon P, *et al.* 1989. *Immunol. Rev.* 111:111.